Transition-metal-free nucleophilic 211At-astatination of spirocyclic aryliodonium ylides
- 4 June 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 19 (25), 5525-5528
- https://doi.org/10.1039/d1ob00789k
Abstract
The transition-metal-free nucleophilic 211At-astatination of aryliodonium ylides, involving those derived from multi-functionalized molecules and heteroarenes, proceeded with good to excellent radiochemical yields.Funding Information
- Japan Society for the Promotion of Science (JP19K22177, JP19K22587)
- Adaptable and Seamless Technology Transfer Program through Target-Driven R and D (JPMJTM19E3)
This publication has 28 references indexed in Scilit:
- Realizing Clinical Trials with Astatine-211: The Chemistry InfrastructureCancer Biotherapy & Radiopharmaceuticals, 2020
- Targeted Alpha Therapy, an Emerging Class of Cancer AgentsJAMA Oncology, 2018
- Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical InvestigationsTargeted Oncology, 2018
- Ionic liquid supported organotin reagents to prepare molecular imaging and therapy agentsOrganic & Biomolecular Chemistry, 2016
- Enigmatic astatineNature Chemistry, 2013
- Production of [211At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle TherapyCancer Biotherapy & Radiopharmaceuticals, 2013
- Molecular Pathways: Targeted α-Particle Radiation TherapyClinical Cancer Research, 2013
- Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting RadionuclidesCurrent Radiopharmaceuticals, 2011
- Radiohalogens for imaging and therapyChemical Society Reviews, 2004
- 1-(meta-[211At]Astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluationBioconjugate Chemistry, 1992